PL2807153T3 - Związki heterocykliczne i sposoby ich zastosowania - Google Patents
Związki heterocykliczne i sposoby ich zastosowaniaInfo
- Publication number
- PL2807153T3 PL2807153T3 PL13741446T PL13741446T PL2807153T3 PL 2807153 T3 PL2807153 T3 PL 2807153T3 PL 13741446 T PL13741446 T PL 13741446T PL 13741446 T PL13741446 T PL 13741446T PL 2807153 T3 PL2807153 T3 PL 2807153T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900286A AU2012900286A0 (en) | 2012-01-25 | "Methods of treatment or prophylaxis" | |
| PCT/AU2013/000061 WO2013110134A1 (en) | 2012-01-25 | 2013-01-25 | Heterocyclic compounds and methods for their use |
| EP13741446.2A EP2807153B1 (en) | 2012-01-25 | 2013-01-25 | Heterocyclic compounds and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2807153T3 true PL2807153T3 (pl) | 2020-09-07 |
Family
ID=48872832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13741446T PL2807153T3 (pl) | 2012-01-25 | 2013-01-25 | Związki heterocykliczne i sposoby ich zastosowania |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150011565A1 (pl) |
| EP (1) | EP2807153B1 (pl) |
| JP (2) | JP6258867B2 (pl) |
| CN (1) | CN104470903B (pl) |
| AU (1) | AU2013202973C9 (pl) |
| CA (1) | CA2861231C (pl) |
| ES (1) | ES2798289T3 (pl) |
| NZ (1) | NZ627560A (pl) |
| PL (1) | PL2807153T3 (pl) |
| PT (1) | PT2807153T (pl) |
| WO (1) | WO2013110134A1 (pl) |
| ZA (1) | ZA201405255B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS55701B1 (sr) | 2011-06-22 | 2017-07-31 | Purdue Pharma Lp | Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| JP6258867B2 (ja) * | 2012-01-25 | 2018-01-10 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| NZ630908A (en) | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
| TR201807959T4 (tr) | 2013-07-22 | 2018-06-21 | Idorsia Pharmaceuticals Ltd | 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri. |
| WO2015063709A1 (en) * | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
| CN107001337B (zh) * | 2015-01-13 | 2021-05-04 | 诺华股份有限公司 | 作为血管紧张素ii型拮抗剂的吡咯烷衍生物 |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| RS58349B1 (sr) | 2015-01-15 | 2019-03-29 | Idorsia Pharmaceuticals Ltd | Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora |
| ES2898635T3 (es) | 2015-03-12 | 2022-03-08 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| CN105503787A (zh) * | 2015-12-31 | 2016-04-20 | 阜阳欣奕华材料科技有限公司 | 一种索非布韦中间体的纯化方法 |
| WO2019040105A2 (en) * | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES |
| EP3724178B1 (en) | 2017-12-15 | 2024-05-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer |
| US12611406B2 (en) | 2020-06-19 | 2026-04-28 | Inthera Bioscience AG | Oxopiperazine derivatives for the treatment of cancer |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400511A (en) * | 1982-05-07 | 1983-08-23 | American Home Products Corporation | 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids |
| US5116842A (en) * | 1989-05-18 | 1992-05-26 | Glaxo Group Limited | Chemical compounds |
| US5292726A (en) * | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5344830A (en) * | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| US5348955A (en) * | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US6340682B1 (en) * | 1996-08-23 | 2002-01-22 | Kowa Co., Ltd. | Diamide compound and drugs containing the same |
| ATE273299T1 (de) * | 1997-06-17 | 2004-08-15 | Schering Corp | Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung |
| US5968938A (en) * | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
| US6951862B2 (en) * | 1998-06-30 | 2005-10-04 | Neuromed Technologies, Inc. | Calcium channel blockers comprising two benzhydril moieties |
| US20060084660A1 (en) * | 1998-06-30 | 2006-04-20 | Neuromed Technologies Inc. | Calcium channel blockers comprising two benzhydril moieties |
| US7589199B2 (en) * | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| JP4579681B2 (ja) * | 2002-07-09 | 2010-11-10 | ブリストル−マイヤーズ スクイブ カンパニー | 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法 |
| DE10309005A1 (de) * | 2003-03-01 | 2004-09-09 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Dipetidyl Peptidase (DPPIV) und Neurale Endopeptidase (NEP) inhibieren |
| CA2562371A1 (en) * | 2004-04-09 | 2005-10-20 | Neuromed Pharmaceuticals Ltd. | Diarylamine derivatives as calcium channel blockers |
| NZ555334A (en) * | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| WO2006086609A2 (en) * | 2005-02-10 | 2006-08-17 | Axys Pharmaceuticals, Inc. | Inhibitors of tryptase |
| US20070049578A1 (en) * | 2005-08-24 | 2007-03-01 | Astrazeneca Ab | Cinnamamide compounds as metabotropic glutamate receptor antagonists |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| WO2007133481A2 (en) * | 2006-05-11 | 2007-11-22 | Neuromed Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| JP2008031064A (ja) * | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2303876B1 (en) | 2008-06-25 | 2014-03-19 | Bristol-Myers Squibb Company | Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
| ES2560327T3 (es) | 2010-01-19 | 2016-02-18 | Novartis Ag | Métodos y composiciones para una velocidad de conducción nerviosa mejorada |
| JP6232384B2 (ja) | 2012-01-06 | 2017-11-15 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
| EP2807171B1 (en) | 2012-01-25 | 2020-08-12 | Novartis AG | Heterocyclic compounds and methods for their use |
| JP6258867B2 (ja) * | 2012-01-25 | 2018-01-10 | ノバルティス アーゲー | 複素環式化合物およびその使用方法 |
-
2013
- 2013-01-25 JP JP2014553581A patent/JP6258867B2/ja active Active
- 2013-01-25 CA CA2861231A patent/CA2861231C/en active Active
- 2013-01-25 EP EP13741446.2A patent/EP2807153B1/en active Active
- 2013-01-25 US US14/373,355 patent/US20150011565A1/en not_active Abandoned
- 2013-01-25 NZ NZ627560A patent/NZ627560A/en unknown
- 2013-01-25 PL PL13741446T patent/PL2807153T3/pl unknown
- 2013-01-25 CN CN201380016259.9A patent/CN104470903B/zh active Active
- 2013-01-25 WO PCT/AU2013/000061 patent/WO2013110134A1/en not_active Ceased
- 2013-01-25 PT PT137414462T patent/PT2807153T/pt unknown
- 2013-01-25 AU AU2013202973A patent/AU2013202973C9/en active Active
- 2013-01-25 ES ES13741446T patent/ES2798289T3/es active Active
-
2014
- 2014-07-17 ZA ZA2014/05255A patent/ZA201405255B/en unknown
-
2016
- 2016-05-09 US US15/149,641 patent/US9708275B2/en active Active
-
2017
- 2017-10-25 JP JP2017205744A patent/JP2018076297A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2807153A1 (en) | 2014-12-03 |
| US20160257656A1 (en) | 2016-09-08 |
| US20150011565A1 (en) | 2015-01-08 |
| JP2018076297A (ja) | 2018-05-17 |
| WO2013110134A1 (en) | 2013-08-01 |
| CN104470903B (zh) | 2017-02-22 |
| JP2015504900A (ja) | 2015-02-16 |
| CA2861231C (en) | 2021-04-13 |
| HK1201533A1 (en) | 2015-09-04 |
| NZ627560A (en) | 2016-08-26 |
| EP2807153B1 (en) | 2020-03-25 |
| ES2798289T3 (es) | 2020-12-10 |
| AU2013202973B9 (en) | 2016-11-24 |
| ZA201405255B (en) | 2019-04-24 |
| AU2013202973C9 (en) | 2016-12-22 |
| US9708275B2 (en) | 2017-07-18 |
| PT2807153T (pt) | 2020-06-18 |
| CN104470903A (zh) | 2015-03-25 |
| AU2013202973B2 (en) | 2016-06-02 |
| AU2013202973C1 (en) | 2016-11-24 |
| EP2807153A4 (en) | 2015-06-10 |
| CA2861231A1 (en) | 2013-08-01 |
| JP6258867B2 (ja) | 2018-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405253B (en) | Heterocyclic compounds and methods for their use | |
| ZA201401434B (en) | Heterocyclic compounds and uses thereof | |
| IL230536A0 (en) | Heterocyclic compounds and their uses | |
| EP2678016A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| SG11201504049VA (en) | Compounds and their methods of use | |
| PL2920149T3 (pl) | Związki 3-aminocykloalkilowe jako inhibitory ror-gamma-t oraz ich zastosowania | |
| ZA201405257B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| AP2015008591A0 (en) | Heterocyclic compounds | |
| EP2832734A4 (en) | HETEROCYCLIC COMPOUND | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| HUE062842T2 (hu) | Új heterociklusos származékok és alkalmazásaik | |
| GB201111705D0 (en) | Compounds and their use | |
| AP3611A (en) | Heterocyclic compounds and their uses | |
| EP2782571A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| PL2882708T3 (pl) | Nowe związki i ich zastosowania | |
| GB201213726D0 (en) | Novel compounds and their use | |
| GB201206973D0 (en) | New compounds and uses | |
| GB201207075D0 (en) | New compounds and uses | |
| GB201206055D0 (en) | New compounds and uses | |
| GB201214749D0 (en) | Compounds and their uses | |
| GB201202400D0 (en) | Nitrogen-containing heterocyclic compounds | |
| GB201104444D0 (en) | Compounds and their use |